Mounjaro 7.5 mg 1 pen
Eli Lilly
Eli Lilly
Composition
Each dose (0.6 mL) contains
Tirzepatide - 7.5 mg.
Each multi-dose pre-filled pen contains 30 mg tirzepatide in 2.4 mL (12,5 mg/mL) of solution.
Excipients
Dibasic sodium phosphate heptahydrate, benzyl alcohol, glycerin, phenol, sodium chloride, sodium hydroxide, hydrochloric acid, and water for injections.
Description
Mounjaro(tirzepatide) is an injectable medicine used for the treatment of type 2 diabetes mellitus.
It acts as a dual GIP and GLP-1 receptor agonist, helping to regulate blood glucose by enhancing glucose-dependent insulin secretion and reducing glucagon release.
It also slows gastric emptying, improving postprandial glucose control and supporting weight reduction in patients with type 2 diabetes.
Properties
Compared to semaglutide, tirzepatide demonstrates greater efficacy in reducing body weight and controlling blood glucose levels in people with diabetes.
Immediately after entering the body, the drug binds to GIP and GLP-1 receptors in the pancreas and stimulates the secretion of insulin.
Insulin helps body cells absorb glucose from the bloodstream, thereby lowering blood sugar levels.
At the same time, the release of glucagon - a hormone that reduces insulin resistance - is suppressed.
This increases tissue sensitivity to insulin and profoundly affects fat metabolism, leading to significant weight loss.
Tirzepatide also acts on appetite regulation centers in the brain, helping individuals feel full more quickly.
This effect is enhanced by the slowing of gastric emptying, allowing food to remain in the stomach longer and prolonging the sensation of satiety.
Indications for Use
Treatment of adults with type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and physical activity.
May be used as monotherapy or in combination with other antidiabetic agents (such as metformin or insulin), as prescribed by a healthcare provider.
Dosage and Method of Administration
Administer subcutaneously (in the abdomen, thigh, or upper arm) once weekly, with or without food.
Dosage should be individualized and titrated gradually to achieve optimal glycemic control.
Each pen delivers 4 doses.
Contraindications
Hypersensitivity to tirzepatide or any excipient.
Type 1 diabetes mellitus or diabetic ketoacidosis.
Severe gastrointestinal disorders, such as gastroparesis.
Precautions
Do not use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Use caution when combined with insulin or sulfonylureas due to risk of hypoglycemia.
In case of severe nausea, vomiting, or dehydration, contact a physician.
Not recommended for patients under 18 years (safety and efficacy not established).
Side Effects
Most common
Nausea, diarrhea, vomiting, decreased appetite, constipation, abdominal pain.
Less common
Hypoglycemia (when used with other antidiabetic drugs), injection site reactions, elevated pancreatic enzymes.
Serious adverse events (e.g., pancreatitis or thyroid disorders) require immediate medical attention.
Pregnancy and Breastfeeding
Not recommended during pregnancy or breastfeeding due to limited data.
Discontinue tirzepatide at least one month before planned conception.
Storage Conditions
Store refrigerated at 2°C to 8°C.
Do not freeze.
After first use, may be stored at room temperature (below 30°C) for up to 30 days.
Keep out of sight and reach of children.
Packaging
A carton box containing 1 pre-filled multi-dose KwikPen (4 doses) for subcutaneous injection.